ERBB2 and cancer: For example, Ertumaxomab with trifunctional structure can simultaneously target HER2-expreesing cancer cells and CD3 antigens on T cells while its Fc region is identified by Fcγ type I/III receptor on tumor-suppressive immune cells [39].